ClinicalTrials.gg
CompletedNCT07683429Updated Jul 6, 2026

Local Corticosteroid Injection Versus Open Surgical Release in De Quervain Tenosynovitis: A Single-Center Study

An interventional study of Triamcinolone acetonide with lidocaine and Open surgical release of first dorsal extensor compartment in DeQuervain's Tenosynovitis, sponsored by Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Mar 2023, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This quasi-experimental study compared pain outcomes following local corticosteroid injection (CSI) versus open surgical release in 100 patients with clinically confirmed De Quervain tenosynovitis unresponsive to conservative management. Patients were allocated to treatment based on clinician judgment and patient preference. Pain was assessed using the Visual Analog Scale (VAS) at baseline, one month, and six months post-intervention. The study was conducted at a single tertiary care centre in Rawalpindi, Pakistan between March 2023 and April 2025.

Read the detailed description

De Quervain tenosynovitis is a stenosing tendinopathy of the first dorsal extensor compartment of the wrist, causing radial-sided wrist pain. One hundred patients were enrolled and allocated to either corticosteroid injection (CSI; n=49) or open surgical release (n=51). The CSI protocol consisted of triamcinolone acetonide (40mg/mL, 1mL) combined with 1% lidocaine (1mL) injected into the first dorsal compartment under aseptic conditions. Surgical release involved longitudinal decompression of the fibro-osseous sheath overlying the APL and EPB tendons. The primary outcome was VAS pain score at baseline, one month, and six months. Statistical analysis included independent t-tests and linear mixed-effects modeling.

02

Conditions studied

  • DeQuervain's Tenosynovitis

Keywords

  • De Quervain tenosynovitis
  • tendinopathy
  • corticosteroid injection
  • quasi-experimental study; wrist
  • surgical release
  • visual analog scale
03

In context

De Quervain Disease

31 studies on the registry are indexed under De Quervain Disease; 8 are open to participants now.

This study's enrollment of 100 is above the median of 49 across 27 interventional studies indexed under De Quervain Disease.

Browse De Quervain Disease studies →

Lead sponsor

Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of De Quervain tenosynovitis confirmed by positive Finkelstein test
  • Age 18-70 years
  • Pain sufficiently severe to impair activities of daily living
  • Failure to respond to at least 4 weeks of conservative management

Exclusion criteria

Exclusion Criteria:

  • Concurrent inflammatory arthropathy (rheumatoid arthritis or gout)
  • History of prior wrist injury
  • Previous surgical or injection treatment for De Quervain tenosynovitis
  • Coexisting upper limb pathology (rotator cuff pathology, epicondylitis, or carpal tunnel syndrome)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Corticosteroid Injection (CSI)

    Single injection of triamcinolone acetonide (40mg/mL, 1mL) combined with 1% lidocaine (1mL) administered into the first dorsal extensor compartment under aseptic conditions without ultrasound guidance.

    Drug: Triamcinolone acetonide with lidocaine

  • Active comparator
    Open Surgical Release

    Open decompression of the first dorsal compartment through a longitudinal incision over the radial styloid, with release of the fibro-osseous sheath overlying the APL and EPB tendons, closed with non-absorbable sutures.

    Procedure: Open surgical release of first dorsal extensor compartment

Interventions

  • DrugTriamcinolone acetonide with lidocaine

    Drug pages: Triamcinolone AcetonideStudies of Triamcinolone AcetonideTriamcinolone Acetonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Triamcinolone acetonide 40mg/mL (1mL) + 1% lidocaine (1mL) - single injection

  • ProcedureOpen surgical release of first dorsal extensor compartment

    Longitudinal decompression of the fibro-osseous sheath overlying APL and EPB tendons

06

What researchers measure

Primary outcomes

  1. Pain intensity - Visual Analog Scale (VAS)

    Pain scored on a 0-10 VAS scale where 0 = no pain and 10 = worst imaginable pain, assessed by a blinded assessor

    Time frame: Time Frame: Baseline, 1 month, and 6 months post-intervention

Secondary outcomes

  1. Adverse events

    Any complications or adverse events recorded in either treatment group

    Time frame: Throughout 6-month follow-up period

07

Study locations

1 site
  • Rawalpindi Teaching Hospital.
    Rawalpindi, Punjab Province 46000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not publicly available due to institutional privacy policies but are available from the corresponding author upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Apr 2025, 25 months.

Of 16 interventional studies with no phase under De Quervain Disease, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 28. This study's 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2026
First posted
Jul 6, 2026
StartActual
Mar 3, 2023
Primary completionActual
Apr 3, 2025
CompletionActual
Apr 20, 2025
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07683429
Lead sponsor
Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi
Responsible party
Osama Ijaz (Post-graduate resident Trauma & Orthopedics, Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi) — Principal investigator
First posted
Jul 6, 2026
Start date
Mar 3, 2023
Primary completion
Apr 3, 2025
Completion
Apr 20, 2025
Last update
Jul 6, 2026

Study contacts

Saad Riaz, FCPS Orthopedic Surgery
study chair · Rawalpindi Teaching Hospital.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Triamcinolone Acetonide · Lidocaine

Start the discussion